This study involved the rational designof dual LSD1–HDACinhibitors as promising anticancer interventions for CRC assembledvia conjugation of key pharmacophores of LSD1 and HDAC inhibitors.The embarkment of this campaign stems from the reports confirmingthe overexpression of LSD1 and HDAC isoforms in CRC. Here, HDAC9 is linked to colorectal carcinoma.